STRN-ALK Fusion in Advanced Salivary Gland Carcinoma With Response to Anaplastic Lymphoma Kinase Inhibition: Case Report and Literature Review.

Salivary gland carcinomas are a heterogeneous group of rare tumors. There is no established standard of care therapy for metastatic disease. We describe the case of a patient with metastatic salivary gland adenocarcinoma harboring STRN-ALK translocation, with tumor response and clinical benefit from anaplastic lymphoma kinase ( ALK ) inhibition. Our patient experienced clinical benefit from first and second generation ALK inhibition in a chemotherapy refractory tumor. Tumor mutation profiling can identify mutations that may render tumors sensitive to targeted therapy with tyrosine kinase inhibitors.
(Copyright© Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc.)